Altitude illness: Risk factors, prevention, presentation, and treatment

American Family Physician

Volumn 82, Issue 9, 2010, Pages 1103-1110

  Fiore, David C ^a   Hall, Scott ^a   Shoja, Pantea ^b  

^a UNIVERSITY OF NEVADA SCHOOL OF MEDICINE   (United States)

^b ST JOSEPH'S HOSPITAL AND MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETAZOLAMIDE; ANTIBIOTIC AGENT; BRADYKININ; CYCLOPLEGIC AGENT; DEXAMETHASONE; DIURETIC AGENT; NIFEDIPINE; NITRIC OXIDE SYNTHASE; NONSTEROID ANTIINFLAMMATORY AGENT; OXYGEN; PHOSPHODIESTERASE V INHIBITOR; SALMETEROL; SALMETEROL XINAFOATE; SILDENAFIL; TADALAFIL; THEOPHYLLINE; VASCULOTROPIN; CARBONATE DEHYDRATASE INHIBITOR; GLUCOCORTICOID;

ACUTE MOUNTAIN SICKNESS; ALTITUDE DISEASE; ANOREXIA; ARTICLE; ASTHMA; CHRONIC DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONGESTIVE HEART FAILURE; CORNEA ABRASION; CORNEA DISEASE; CORONARY ARTERY DISEASE; DIZZINESS; DRUG CONTRAINDICATION; DRUG EFFICACY; FATIGUE; GINKGO BILOBA; HEADACHE; HEART ARRHYTHMIA; HIGH ALTITUDE CEREBRAL EDEMA; HIGH ALTITUDE PULMONARY EDEMA; HUMAN; HYPERTENSION; INCIDENCE; KERATITIS; LOW DRUG DOSE; NAUSEA; OXYGEN THERAPY; PATHOPHYSIOLOGY; PRACTICE GUIDELINE; PULMONARY HYPERTENSION; RADIATION PROTECTION; REST; RISK FACTOR; SICKLE CELL ANEMIA; SLEEP DISORDER; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; TREATMENT INDICATION; VOMITING; WEAKNESS; ACCLIMATIZATION;

ACCLIMATIZATION; ACETAZOLAMIDE; ALTITUDE SICKNESS; CARBONIC ANHYDRASE INHIBITORS; DEXAMETHASONE; GLUCOCORTICOIDS; HUMANS; RISK FACTORS;

EID: 79952116898     PISSN: 0002838X     EISSN: 0002838X     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Murdoch DR. Altitude illness among tourists flying to 3740 meters elevation in the Nepal Himalayas. J Travel Med. 1995;2(4):255-256.
2. Honigman B, Theis MK, Koziol-McLain J, et al. Acute mountain sickness in a general tourist population at moderate altitudes [published correction appears in Ann Intern Med. 1994;120(8):698]. Ann Intern Med. 1993;118(8):587-592.
3. Hackett PH, Rennie D, Levine HD. The incidence, importance, and prophylaxis of acute mountain sickness. Lancet. 1976;2(7996):1149-1155.
4. Basnyat B, Murdoch DR. High-altitude illness. Lancet. 2003;361(9373):1967-1974.
5. Wagner DR, Fargo JD, Parker D, Tatsugawa K, Young TA. Variables contributing to acute mountain sickness on the summit of Mt Whitney. Wilderness Environ Med. 2006;17(4):221-228.
6. Wu T, Ding S, Liu J, et al. Ataxia: an early indicator in high altitude cerebral edema. High Alt Med Biol. 2006;7(4):275-280.
7. Hackett PH, Roach RC. High-altitude illness. N Engl J Med. 2001;345(2):107-114.
8. Murdoch D. Altitude sickness. Clin Evid. 2005;(14):1570-1575.
9. Schneider M, Bernasch D, Weymann J, Holle R, Bartsch P. Acute mountain sickness: influence of susceptibility, preexposure and ascent rate. Med Sci Sports Exerc. 2002;34(12):1886-1891.
10. Pesce C, Leal C, Pinto H, et al. Determinants of acute mountain sickness and success on Mount Aconcagua (6962 m). High Alt Med Biol. 2005;6(2):158-166.
11. Basnyat B, Lemaster J, Litch JA. Everest or bust: a cross sectional, epidemiological study of acute mountain sickness at 4243 meters in the Himalayas. Aviat Space Environ Med. 1999;70(9):867-873.
12. Sutton JR, Coates G, Houston CS. Hypoxia and Mountain Medicine. Burlington, Vt.: Queen City Printers; 1992.
13. High Altitude Medicine Guide. The Lake Louise consensus on the definition of altitude illness. http://www.high-altitude-medicine.com/AMS-LakeLouise.html. Accessed August 24, 2010.
14. High Altitude Medicine Guide. AMS worksheet. http://www.high-altitude-medicine.com/AMS-worksheet.html. Accessed July 15, 2010.
15. Roeggla G, Roeggla M, Podolsky A, Wagner A, Laggner AN. How can acute mountain sickness be quantified at moderate altitude? J R Soc Med. 1996;89(3):141-143.
16. van Patot MC, Leadbetter G III, Keyes LE, Maakestad KM, Olson S, Hackett PH. Prophylactic low-dose acetazolamide reduces the incidence and severity of acute mountain sickness. High Alt Med Biol. 2008;9(4):289-293.
17. Basnyat B, Gertsch JH, Holck PS, et al. Acetazolamide 125 mg BD is not significantly different from 375 mg BD in the prevention of acute mountain sickness: the prophylactic acetazolamide dosage comparison for efficacy (PACE) trial. High Alt Med Biol. 2006;7(1):17-27.
18. Ellsworth AJ, Meyer EF, Larson EB. Acetazolamide or dexamethasone use versus placebo to prevent acute mountain sickness on Mount Rainier. West J Med. 1991;154(3):289-293.
19. Reid LD, Carter KA, Ellsworth A. Acetazolamide or dexamethasone for prevention of acute mountain sickness:a meta-analysis. J Wilderness Med. 1994;5:34-48.
20. Küpper TE, Strohl KP, Hoefer M, Gieseler U, Netzer CM, Netzer NC. Low-dose theophylline reduces symptoms of acute mountain sickness. J Travel Med. 2008;15(5):307-314.
21. Kasic JF, Yaron M, Nicholas RA, Lickteig JA, Roach R. Treatment of acute mountain sickness: hyperbaric versus oxygen therapy. Ann Emerg Med. 1991;20(10):1109-1112.
22. van Patot MC, Keyes LE, Leadbetter G III, Hackett PH. Ginkgo biloba for prevention of acute mountain sickness: does it work? High Alt Med Biol. 2009;10(1):33-43.
23. Leadbetter G, Keyes LE, Maakestad KM, Olson S, Tissot van Patot MC, Hackett PH. Ginkgo biloba does-and does not-prevent acute mountain sickness. Wilderness Environ Med. 2009;20(1):66-71.
24. Maggiorini M, Brunner-La Rocca HP, Peth S, et al. Both tadalafil and dexamethasone may reduce the incidence of high-altitude pulmonary edema: a randomized trial. Ann Intern Med. 2006;145(7):497-506.
25. Sartori C, Allemann Y, Duplain H, et al. Salmeterol for the prevention of high-altitude pulmonary edema. N Engl J Med. 2002;346(21):1631-1636.
26. Luks AM. Do we have a "best practice" for treating high altitude pulmonary edema? High Alt Med Biol. 2008;9(2):111-114.
27. Fagenholz PJ, Gutman JA, Murray AF, Harris NS. Treatment of high altitude pulmonary edema at 4240 m in Nepal. High Alt Med Biol. 2007;8(2):139-146.
28. Zafren K, Honigman B. High-altitude medicine. Emerg Med Clin North Am. 1997;15(1):191-222.
29. Dumont L, Mardirosoff C, Tramèr MR. Efficacy and harm of pharmacological prevention of acute mountain sickness: quantitative systematic review. BMJ. 2000;321(7256):267-272.
30. Maggiorini M, Mélot C, Pierre S, et al. High-altitude pulmonary edema is initially caused by an increase in capillary pressure. Circulation. 2001;103(16):2078-2083.
31. Eldridge MW, Braun RK, Yoneda KY, Walby WF. Effects of altitude and exercise on pulmonary capillary integrity: evidence for subclinical high-altitude pulmonary edema. J Appl Physiol. 2006;100(3):972-980.
32. Swenson ER, Maggiorini M, Mongovin S, et al. Pathogenesis of high-altitude pulmonary edema: inflammation is not an etiologic factor [published correction appears in JAMA. 2002;288(9):1064]. JAMA. 2002;287(17):2228-2235.
33. Voelkel NF. High-altitude pulmonary edema. N Engl J Med. 2002;346(21):1606-1607.
34. Maggiorini M, Bühler B, Walter M, Oelz O. Prevalence of acute mountain sickness in the Swiss Alps. BMJ. 1990;301(6756):853-855.
35. Kobayashi T, Koyama S, Kubo K, Fukushima M, Kusama S. Clinical features of patients with high-altitude pulmonary edema in Japan. Chest. 1987;92(5):814-821.
36. Jafarian S, Gorouhi F, Ghergherechi M, Lotfi J. Respiratory rate within the first hour of ascent predicts subsequent acute mountain sickness severity. Arch Iran Med. 2008;11(2):152-156.
37. Basnyat B, Hargrove J, Holck PS, et al. Acetazolamide fails to decrease pulmonary artery pressure at high altitude in partially acclimatized humans. High Alt Med Biol. 2008;9(3):209-216.
38. Wiedman M, Tabin GC. High-altitude retinopathy and altitude illness. Ophthalmology. 1999;106(10):1924-1926.
39. Weaver CS, Terrell KM. Evidence-based emergency medicine. Update: do ophthalmic nonsteroidal anti-inflammatory drugs reduce the pain associated with simple corneal abrasion without delaying healing? Ann Emerg Med. 2003;41(1):134-140.
40. Turner A, Rabiu M. Patching for corneal abrasion. Cochrane Database Syst Rev. 2006;(2):CD004764.
41. Mader TH, Blanton CL, Gilbert BN, et al. Refractive changes during 72-hour exposure to high altitude after refractive surgery. Ophthalmology. 1996;103(8):1188-1195.
42. Alexander JK. Coronary problems associated with altitude and air travel. Cardiol Clin. 1995;13(2):271-278.
43. Roach RC, Houston CS, Honigman B, et al. How well do older persons tolerate moderate altitude? West J Med. 1995;162(1):32-36.
44. Erdmann J, Sun KT, Masar P, Niederhauser H. Effects of exposure to altitude on men with coronary artery disease and impaired left ventricular function. Am J Cardiol. 1998;81(3):266-270.
45. Hultgren HN. Effects of altitude upon cardiovascular diseases. J Wilderness Med. 1992;3:301-308.
46. Lane PA, Githens JH. Splenic syndrome at mountain altitudes in sickle cell trait. Its occurrence in nonblack persons. JAMA. 1985;253(15):2251-2254.
47. Green RL, Huntsman RG, Serjeant GR. The sickle-cell and altitude. Br Med J. 1971;4(5787):593-595.
48. Brubaker PL. Adventure travel and type 1 diabetes: the complicating effects of high altitude. Diabetes Care. 2005;28(10):2563-2572.